Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. by Vieira, Debora F et al.
UC San Diego
UC San Diego Previously Published Works
Title
Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting 
Trypanosoma cruzi CYP51.
Permalink
https://escholarship.org/uc/item/3j62x4nt
Journal
Journal of medicinal chemistry, 57(23)
ISSN
0022-2623
Authors
Vieira, Debora F
Choi, Jun Yong
Calvet, Claudia M
et al.
Publication Date
2014-12-01
DOI
10.1021/jm501568b
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Binding Mode and Potency of N‑Indolyloxopyridinyl-4-
aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51
Debora F. Vieira,†,‡ Jun Yong Choi,∥ Claudia M. Calvet,# Jair Lage Siqueira-Neto,†,‡,∞
Jonathan B. Johnston,§ Danielle Kellar,†,‡,× Jiri Gut,† Michael D. Cameron,⊥ James H. McKerrow,†,‡,∞
William R. Roush,*,∥ and Larissa M. Podust*,†,‡,∞
†Center for Discovery and Innovation in Parasitic Diseases, ‡Department of Pathology, and §Department of Pharmaceutical
Chemistry, University of CaliforniaSan Francisco, San Francisco, California 94158, United States
∥Department of Chemistry, and ⊥Department of Molecular Therapeutics, Scripps Florida, Jupiter, Florida 33458, United States
#Cellular Ultra-Structure Laboratory, Oswaldo Cruz Institute (IOC), FIOCRUZ, Rio de Janeiro, Rio de Janeiro 21040-362, Brazil
*S Supporting Information
ABSTRACT: Chagas disease is a chronic infection in humans caused by Trypanosoma cruzi and manifested in progressive
cardiomyopathy and/or gastrointestinal dysfunction. Limited therapeutic options to prevent and treat Chagas disease put 8
million people infected with T. cruzi worldwide at risk. CYP51, involved in the biosynthesis of the membrane sterol component
in eukaryotes, is a promising drug target in T. cruzi. We report the structure−activity relationships (SAR) of an N-arylpiperazine
series of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors designed to probe the impact of substituents in the terminal N-
phenyl ring on binding mode, selectivity and potency. Depending on the substituents at C-4, two distinct ring binding modes,
buried and solvent-exposed, have been observed by X-ray structure analysis (resolution of 1.95−2.48 Å). The 5-chloro-
substituted analogs 9 and 10 with no substituent at C-4 demonstrated improved selectivity and potency, suppressing ≥99.8%
parasitemia in mice when administered orally at 25 mg/kg, b.i.d., for 4 days.
■ INTRODUCTION
Chagas disease, prevalent in Latin America, is caused by chronic
infection by Trypanosoma cruzi, a protozoon transmitted in
nature by the bite of the Triatominae insect vector. Following
an initial stage, which can be either acute or asymptomatic, T.
cruzi invades the heart, gastrointestinal tract, or nervous system,
where it may persist asymptomatically for years before
manifesting in cardiomyopathy, megacolon, and megaesopha-
gus syndromes.1 Nifurtimox and benznidazole are the only two
medicines currently available for treatment of Chagas disease.
Both drugs are notorious for adverse gastrointestinal and
neurological side effects.2 Against the initial acute stage of
infection benznidazole is about 80% effective,3 but in the much
longer and epidemiologically prevalent chronic stage its efficacy
is controversial. While the efficacy and safety of benznidazole in
patients with chronic Chagas disease are being investigated in
the ongoing clinical trials BENEFIT4,5 and TRAENA,6
significant efforts have been made to repurpose antifungal
azole drugs for Chagas disease patients. These efforts led to
recent clinical trials of posaconazole7,8 (Noxafil, Merck) and
ravuconazole9 (Eisai, Tokyo). Both drugs target sterol 14-
demethylase (CYP51), a clinically validated drug target for
fungal infections and a promising therapeutic target in T.
cruzi.10 However, both drugs’ disappointingly low efficacy
against Chagas over long time frames demonstrates the need
for further trials, at different doses or in combination with
benznidazole.11 Discovery of new anti-Chagasic agents thus
remains a high research priority.
While antifungal drugs like posaconazole and ravuconazole
are effective against T. cruzi in vitro and in experimental animal
models, they were not designed or optimized specifically for the
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T. cruzi CYP51 target. An alternative structure-based approach
has emerged over the past decade that focuses on optimization
of diverse new chemical scaffolds specifically targeting T. cruzi
CYP51.12 This approach is augmented by monitoring the key
pharmacokinetic parameters for anti-Chagas therapy: large
volume of distribution and long terminal half-life.13−16 Starting
points for these efforts have been identified via phenotypic or
target-based screens or by repurposing drug candidates aimed
at other diseases.12 Thus, promising lead compound series have
emerged from the efforts of DNDi (fenarimol analogs),14−16
University of Washington (tipifarnib analogs),17−21 Vanderbilt
(VNI/VNF),22−24 Northeastern (NEU321),25 and finally, the
UCSF-Scripps Florida collaboration (N-indolyloxypyridinyl-4-
aminopropanyl derivatives),13,26−28 among others (Figure 1).
While sharing common structural features, the new compounds
studied by these investigators belong to chemically distinct
classes such as imidazole, triazole, pyridine, and pyrimidine
derivatives.12 This classification is based on the structure of the
heme Fe-coordinating aromatic heterocycle present in each
inhibitor.
The N-indolyloxopyridinyl-4-aminopropanyl-based series
being developed de novo by our collaborative research team
derives from the target-based high throughput screening hit
LP10.29,30 Having carried out a detailed review of the features
and binding mode of the S-enantiomers of first generation
analogs of the initial hit,26 we switched to the R-enantiomer as
the basis for design of next generation inhibitors and developed
the R-enantiomer series of CYP51 inhibitors that are more than
1000 times more potent against T. cruzi infected cells than the
first generation inhibitors.27 In the course of this work, further
optimized inhibitors gained increased stability in liver micro-
some extracts, improved selectivity over human CYPs,27,28 and
demonstrated oral bioavailability and potency in an animal
model of T. cruzi infection.13 Binding modes of three different
scaffold variants, the biaryl,26,27 sulfonamide,28 and N-
arylpiperazine13 series, so named based on the structure of
the longest substituent at the chiral carbon center, have been
characterized by X-ray crystallography. Insertion of the
piperazine moiety between the aryl groups of the biaryl scaffold
enhanced drug−target interactions of the N-arylpiperazine
inhibitors by increasing the number of target-specific contacts
outside the heme pocket.13
To maximize target-specific interactions, modifications of the
terminal N-aryl ring of the N-arylpiperazine scaffold were
systematically explored in this work. As a result, >99.8%
inhibition of parasitemia in mice was attained by oral
administration of compounds 9 and 10 at 25 mg/kg, b.i.d.,
for 4 consecutive days. Significantly, for the first time with the
N-indolyloxopyridinyl-4-aminopropanyl-based series, a substan-
tial decline in off-target inhibition of the most persistent human
Figure 1. CYP51 inhibitors aimed at kinetoplastid parasites. Distances between the Fe-coordinating nitrogen atom and ring 2 are expressed in the
number of bonds (n) highlighted in blue. The PDB codes of corresponding structures are shown in parentheses. Ligands are labeled by their small-
molecule codes. Images were generated using PYMOL.49 Primary citations for the cited structures are as following: 4C0C,13 4H6O,25 3GW9,50
3KSW,51 3ZG3,52 and 3TIK.53
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CYP isoform, CYP2C9, was achieved (compound 9), while
selectivity over other human drug-metabolizing CYPs notably
improved. The binding mode of three new compounds was
assessed by X-ray structure analysis to a resolution ranging
between 1.95 and 2.48 Å, which demonstrated that substituents
at C-4 of the terminal N-phenyl ring controlled a switch
between the two distinct ring-binding modes, referred to here
as buried and solvent-exposed. The most potent inhibitors in
this series retained a 5-chloro substituent but, to gain access to
the buried site, tolerated at most a small fluoro substituent at C-
4. Correlation of inhibitor structure, binding mode, and
potency emphasizes the indispensable role for cocrystal
structures in the design of parasite-specific interactions into
CYP51 inhibitors to advance the discovery of much-needed
potent anti-Chagas antibiotics.
■ RESULTS
Synthesis of New N-Arylpiperazine Compounds.
Eleven new N-arylpiperazine analogs (3−13) with different
substitution patterns in the terminal N-phenyl ring were
synthesized and tested in this work (Table 1). Syntheses of
compounds 3−13 are summarized in Scheme 1. Briefly,
palladium-mediated coupling of methyl 4-bromo-2-fluoroben-
zoate (14) with various N-arylpiperazines served as the key step
for the syntheses of intermediates 15a−25a. Intermediates
15a−25a were then hydrolyzed under basic conditions to
provide carboxylic acid intermediates 15b−25b. These
carboxylic acids were coupled with D-tryptophan derivative 26
to provide the final compounds 3−13. The detailed synthetic
procedures and spectroscopic data for the final products and
synthetic intermediates are available in Experimental Proce-
dures or Supporting Information.
Binding to the CYP51 Target. As previously dis-
cussed,13,31 because of low sensitivity of the UV−vis assay,
true KD values cannot be deduced from UV−vis binding curves
of the tight-binding CYP51 inhibitors. Accordingly, the binding
curves obtained by the UV−vis titration of the CYP51 target at
1 μM (Figure S1A) reached a plateau at equimolar
concentrations (with the exception of compounds 5, 6, 7,
and 9), suggesting low nanomolar binding affinity. The binding
curves for 5, 6, 7, and 9 did not reach saturation at equimolar
concentrations, suggesting a drop in binding affinity or possibly
compound solubility issues. The binding behavior correlated
well with the EC50 values in the single digit nanomolar range
for the majority of compounds (Table 1). Slightly higher EC50
values were recorded for compounds 4 (92 nM) and 5 (36
nM), compared to other compounds presented in this study.
Anti T. cruzi Activity in Cell-Based Assay. All 11 newly
synthesized N-arylpiperazine analogs were tested in our
standard cell-based T. cruzi assay; the EC50 curve for each
Table 1. Impact of the Terminal N-Phenyl Ring Structure on Biological Activity
aThe terminal N-phenyl rings of the compounds are depicted in orientations deduced from the X-ray structure analysis and SAR. bEach
measurement performed in triplicate (see Supporting Information). cEach measurement is an average of five mice treated with 25 mg/kg (20%
Kolliphor), po, b.i.d., for 4 days. dStability of compounds in human (h), rat (r), and mouse (m) liver microsomes as evaluated compared to the
sunitinib reference. eInhibition of CYPs as evaluated in human liver microsomes using selective marker substrates for each CYP. fThere was one
outlier in this group with no effect of the compound (signal comparable to untreated controls, see Figure S3). gN/D: not determined. hCompounds
1 and 2 have been previously characterized.13
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compound is provided in Figure S1B. Compounds 3 and 7−12
demonstrated EC50 in the single digit nanomolar range (Table
1), an order of magnitude improvement compared to the
previously reported analogs 1 (29 nM) and 2 (17 nM).13
Compounds 6 (12 nM) and 13 (17 nM) retained potency at
compound 2 level, while compounds 4 (92 nM) and 5 (36 nM)
were notably less potent among those featured in Table 1.
Potency in the cell-based assay is consistent with tight binding
affinity.
Metabolic Stability and CYP Selectivity. Attenuated
metabolic stability and the selectivity of human drug-
metabolizing CYPs are two major drawbacks of the previously
studied N-arylpiperazine scaffold members that were specifically
addressed in this work. In the newly synthesized and tested
compound series, compound 9 showed improvement in both
microsome stability and CYP selectivity compared to the
previously characterized compounds 1 and 2.13 Inhibition of
CYP2C9, the most persistent human isoform, dropped to 69%
at 1 μM, which favorably compares to the ≥90% inhibition of
CYP2C9 previously observed for the majority of N-
indolyloxopyridinyl-4-aminopropanyl inhibitors.13,26−28 Half-
life in liver microsome preparations also improved, reaching
>30 min in both mouse and rat liver microsomes. Stability of
these compounds in human liver microsomes remained
comparable to that of compound 1.
Scheme 1. Synthesis of the N-Arylpiperazine Compounds 3−13a
aReagents and conditions: (a) 1-(aryl)piperazine, Pd(OAc)2, P(o-tolyl)3, Cs2CO3, toluene, 50 °C, 48 h, ∼60%; (b) 10% NaOH (aq), MeOH/THF
(1/1), 60 °C, 3 h, >98%; (c) 15b, 16b, 17b, 18b, 19b, 20b, 21b, 22b, 23b, 24b, or 25b (as appropriate), PyBOP, HOBt, Et3N, CH2Cl2, 23 °C, 1 h,
∼60%.
Table 2. PK Parameters for Compounds 9 and 10
single dose PK parametersa
compd T1/2 (h) Tmax (h) Cmax (μM) AUClast (μM·h) VD (L/kg) Clobs (mL min
−1 kg−1)
9 3.86 4.67 1.85 22.48 3.97 30.50
10 2.99 3.33 1.8 19.01 3.44 35.73
aEach measurement is an average of three mice that received a single 25 mg/kg dose of test compound at 5 mg/mL suspension in 20% Kolliphor.
See Figure S2 for details.
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Pharmacokinetic Properties. Pharmacokinetic (PK)
parameters in mice were calculated from plasma concentration
versus time curves obtained for two compounds, 9 and 10,
orally single-dosed at 25 mg/kg as 5 mg/mL suspensions in
20% Kolliphor (Table 2). Both compounds had good oral
exposure and were absorbed over an extended period, resulting
in low micromolar drug levels in plasma between 2 and 8 h
(Figure S2). Relatively stable submicromolar drug concen-
trations were maintained up to 12 h. After 24 h, plasma
concentrations were still an order of magnitude above EC50.
Compound 9 was metabolically more stable than 10, had
higher serum concentration 24 h postexposure, and had higher
volume of distribution (VD) of 3.97 versus 3.44, respectively
(Table 2). The determined values suggest extensive extrava-
scular distribution and penetration into tissues, with the
qualification that they may be affected by an error associated
with oral absorption; VD calculation assumes 100% absorption
and is commonly determined upon iv injection. Consistent with
large volume of distribution, high tissue tropism was previously
observed in mice for the closely related analogs.13 For
comparison, posaconazole VD in humans varies from
approximately 5 to 25 L/kg depending on dosage regimen
and food.32 Posaconazole absorption is enhanced by food, with
400% increase in bioavailability when administered with a high-
fat meal.33
Efficacy in the Animal Model. Selected compounds 3−5
and 9−13 were tested at 25 mg/kg, po, b.i.d., in a 4-day animal
model of infection by a transgenic T. cruzi strain expressing
firefly luciferase. (Figure 2 and Figure S3). The parental T. cruzi
strain was originally designated as T. cruzi Y (TcII),34 but strain
identity was later confirmed to be Brazil (TcI).35 This identity
clarification is consistent with attenuated infectivity and self-
clearance of parasites documented in our earlier work,13 which
contrasts with typical behavior of T. cruzi Y strain. In this work
we continued to use the same strain, now called T. cruzi Brazil
luc, for short-term assessment of bioavailability and potency of
test compounds. A 25 mg/kg dose, proven more informative
for rank ordering of the N-indolyloxopyridinyl-4-amino-
propanyl inhibitors than a 50 mg/kg dose,13 was used in
these studies. The ability of most of the newly synthesized
compounds to suppress parasite growth in the 4-day animal
model was improved relative to previously tested analogs 1
(90.2%) and 2 (87.4%), with the exception of compounds 5
and 13 which showed 71.5% and 80.3% inhibition, respectively
(Table 1). In particular, compounds 9−12, inhibiting >98.5%
parasitemia, were more potent than compounds 3 (93.7%) and
4 (96.8%). The most efficacious compounds 9 and 10 attained
≥99.8% inhibition and were superior to benznidazole
administered at 25 mg/kg (Figure 2 and Figure S3). On the
basis of these SAR data, we conclude that the 5-chloro
substituent on the terminal phenyl ring, combined with
unmodified C-4 or C-4 substituted with a small fluorine
atom, was a prerequisite for the highest anti-T. cruzi activity.
Inhibition of Sterol Biosynthesis in T. cruzi Amasti-
gotes. To confirm the mechanism of action, the two most
potent compounds, 9 and 10, have been tested for disruption of
the sterol biosynthesis in intracellular T. cruzi amastigotes. The
assay was conducted as described elsewhere.13,31,36 Lipids
extracted from intracellular amastigotes were analyzed by gas
chromatography and mass spectrometry (GC−MS) and
identified as described previously.37 DMSO (vehicle), K777,
and benznidazole were used as negative controls; posaconazole
served as positive control. The major sterol observed in
untreated amastigotes was episterol (Figure 3, peak d),
followed by approximately equal amounts of fecosterol (e)
and cholesta-7,24-dien-3β-ol (peak a). As a result of treatment,
two 14-methylated precursors, lanosterol (f) and eburicol (h),
dominated the GC−MS traces of the CYP51 inhibitors
posaconazole and compounds 9 and 10, with concomitant
decline in episterol (d) and virtually disappearance of fecosterol
(e) and other 14-demethylated intermediates. Cholesterol was
the only peak originating from the host cells. No changes in
lipid composition have been observed in K777- and
benznidazole-treated samples. Both control drugs have different
mechanism of action. K777 (also known as K11777) is a potent
T. cruzi inhibitor targeting protease cruzain,38 while benznida-
zole acts nonspecifically via production of toxic metabolites.39
On the basis of this experiment, we conclude that in the course
of hit-to-lead optimization compounds of the N-indolyloxopyr-
idinyl-4-aminopropanyl-based SAR series retained the mecha-
nism of action of the parental hit LP1037 and specifically target
T. cruzi CYP51.
Buried and Exposed Binding Modes Determined by
X-ray Crystallography. Three new drug−target complexes
for compounds 3, 4, and 10 have been structurally
characterized to resolution of 2.04, 1.95, and 2.48 Å,
respectively (Table 3). Together with the cocrystal structures
for compounds 1 and 2 reported previously,13 the compound
10 cocrystal structure reported here details at the atomic level
Figure 2. Anti T. cruzi efficacy of compounds in 4-day mouse model of
infection. In two independent experiments (A, B), compounds were
administered at 25 mg/kg, po, b.i.d. Each data point is an average of
five mice (see Figure S3 for original animal images). Benznidazole
(BNZ) at 25 and 50 mg/kg served as a positive control. Percent
inhibition for each compound is calculated relative to the vehicle-
treated control on day 7 postinfection. Percent values are significantly
different than vehicle-treated control (p ≤ 0.05) except for compound
5 where one mice in the group failed treatment (Figure S3).
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the interactions of the substituted terminal N-phenyl ring with
the amino acid landscape of the buried cavity at the end of the
hydrophobic tunnel spanning the β-domain of CYP51 (Figure
4A). Remarkably, substituents at C-4 larger than fluorine could
not be accommodated in this buried cavity. Thus, the 4-chloro-
and 4-trifluoromethyl-substituted terminal rings of 3 and 4
respectively were expelled from the protein interior into the
solvent-exposed entrance of the tunnel separating the α- and β-
domains (Figure 4B). The binding mode switch was enabled by
the flexibility of the piperazine ring, which in 3 and 4 restored
the coplanar, sp2-hybridized arrangement with the nitrogen-
linked terminal N-phenyl ring, thereby alleviating the conforma-
tional distortion of this unit imposed in the bound poses of
compounds 1, 2, and now 10.13 The exposure to the bulk
Figure 3. Sterol profile of T. cruzi amastigotes infecting mouse myoblasts analyzed by GC−MS. C2C12 uninfected mouse myoblasts display a large
peak corresponding to cholesterol (Chol). This is the only peak originating from the host cells. T. cruzi infected cultures also show parasite-specific
lipids corresponding to chromatographic peaks labeled as the following: (a) cholesta-7,24-dien-3β-ol, [M]•+ = m/z 454, tR = 12.51−12.74; (b)
cholesta-8,24-diene-3β-ol (zymosterol), m/z = 470, tR = 12.81−12.86 min; (c) 24-methyl-7-en-cholesta-en-3β-ol, m/z = 472, tR = 12.91−12.93 min;
(d) ergosta-7,24-diene-3-β-ol (episterol), m/z = 470, tR = 13.2−13.5 min; (e) ergosta-8,24-diene-3-β-ol (fecosterol), m/z = 470, tR = 13.5−13.7 min;
(f) lanosterol, m/z 498, tR = 13.95−14.06 min; (g) 4-methylepisterol, m/z = 484, tR = 14.55−14.75 min; (h) eburicol, m/z = 512, tR = 14.8−14.86
min; (i) 24-ethyl-7,24(24′)-en-cholestadiene-3β-ol, m/z = 484, tR = 15.14−15.30 min. Treatment of cultures was performed as indicated in each
panel. DMSO (vehicle), benznidazole, and K777 were used as negative controls. Posaconazole, a potent CYP51 inhibitor, was used as positive
control. Treatment of cultures with compounds 9 and 10 resulted in accumulation of lanosterol (f) and eburicol (h) and decline of episterol (d),
fecosterol (e), and other 14-demethylated intermediates (a, b), indicating the inhibition of CYP51.
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solvent in 3 and 4 is reminiscent of that in posaconazole40
(Figure 5), with the qualification that the N-arylpiperazine
moiety of 3 and 4 is less accessible to the bulk solvent and
makes fewer contacts with the binding tunnel mouth than the
posaconazole terminal unit.40
Collectively, the 1, 2, and 10 cocrystal structures
demonstrated that in the buried mode fluorine and methyl at
C-2, fluorine at C-3 and C-4, and chlorine at C-5 positions of
the terminal N-phenyl ring are tolerated (Figure 6A). The
bulky 5-chloro substituent established multiple van der Waals
contacts with V77, M358, M360, I379, and A381 (Figure 6B),
enhancing target-specific interactions, consistent with gain of
biological activity for compounds 9−12 carrying the 5-chloro
substituent (Table 1). The less extensive range of van der Waals
interactions of the 2-methyl substituent in compound 10 was
limited to I45 and F48 and was established at the cost of
repositioning the F48 side chain from its arrangement in
analogs 1 and 2 (Figure 6A). No other major differences have
been observed between the cocrystal structures of 1, 2, and 10.
The increased size of the 2-oxymethyl substituent in the
terminal aryl ring of compound 13 is consistent with a notable
drop of the in vivo activity (Table 1), likely due to interference
with I45.
Terminal N-Phenyl Ring Substitution Pattern. With no
ambiguity in terminal ring orientation in any of the reported X-
ray structures, we assume that compounds 6−8, all carrying
bulky substituents at C-4, bind in solvent-exposed mode, while
compounds 9, 11, and 12 are likely to bind in buried mode. On
the basis of these assumptions, we speculate that large
substituents, such as Cl or CH3, can be tolerated at C-2, C-3,
and C-5 but not at C-4 (Figure 6C). Hypothetically, if the 5-
chloro substituent of compound 11 makes the same contacts as
its counterpart in 10, a bulky chloro substituent should be
tolerated at C-6. Otherwise, the terminal N-phenyl ring of 11
may be flipped in the buried cavity compared to the ring
orientation observed in 10, placing its two chloro-substituents
at C-2 and C-3 positions. We have not obtained a cocrystal
structure of compound 11 to resolve this potential ambiguity
and will rely on molecular docking-driven hit-to-lead
optimization to find out if further ring chlorination will
Table 3. Data Collection and Refinement Statisticsa
protein
CYP51 CYP51 CYP51
PDB code 4C28 4C27 4UVR
compd 3 4 10
small molecule indentification TW5 26N J5Y
Data Collection
space group P212121 P212121 P6322
cell dimensions
a, b, c (Å) 72.95, 79.00, 176.84 73.1, 79.16, 176.95 128.12, 128.12, 117.78
α, β, γ (deg) 90, 90, 90 90, 90, 90 90, 90, 120
molecules in au 2 2 1
wavelength (Å) 1.115 87 1.115 87 1.115 87
resolution (Å) 2.04 1.95 2.48
Rsym or Rmerge (%) 6.9 (53.5) 16.9 (146) 21.6 (179.5)
I/σI 9.9 (1.6) 8.3 (1.5) 11.5 (1.8)
completeness (%) 86.4 (47.8) 99.5 (96.4) 100 (100)
redundancy 3.5 (2.0) 7.4 (6.7) 15.2 (15.6)
Crystallization Conditions
0.4 M ammonium acetate 0.4 M ammonium acetate 0.25 M ammonium sulfate
0.1 M sodium acetate, pH 4.5 0.1 M sodium acetate, pH 4.5 0.1 M sodium acetate, pH 5.6
28% PEG 3350 28% PEG 3350 25% PEG 3350
5% Jeffamine M-600, pH 7.0 2% 2,5-hexanediol
Refinement
no. reflections 54 178 71 040 19 783
Rwork/Rfree (%) 18.6/23.7 18.3/23.3 19.2/25.3
no. atoms
protein 7063 7161 3397
heme 86 86 43
inhibitor 172 138 44
solvent 410 427 33
mean B value 25.02 28.178 41.1
B-factors
protein 25.2 28.3 42.4
heme 18.1 21.6 29.0
inhibitor 18.3 21.5 36.5
solvent 26.3 31.6 32.1
rms deviation
bond length (Å) 0.017 0.019 0.014
bond angle (deg) 1.911 1.979 1.687
aValues in parentheses are for highest-resolution.
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increase potency of the N-arylpiperazine series, as may be
assumed based on the current studies.
Induced Fit Binding Mechanism. Differences in the
protein conformation between buried and solvent-exposed
binding modes were observed, which are likely due to the
induced fit mechanism associated with inhibitor binding.
Collectively, data accumulated by our research team on the
N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors13,28
challenge speculations in the literature about CYP51’s
“rigidity”.41,42 As suggested by X-ray structure analysis, the
conformational dynamics of the CYP51 backbone are rather
Figure 4. Terminal phenyl ring structures and binding modes: (A)
buried binding mode; (B) solvent-exposed binding mode. Slices
through the binding site show bound inhibitors (yellow spheres) and
the protein surface colored by hydrophobicity; hydrophobic areas are
in orange, and hydrophilic areas are in blue. Heme is in dark-red
spheres. C-4 position in the terminal phenyl ring is labeled by a
number. PDB codes for protein structures and small-molecule ligands
are shown in parentheses. Images were generated using CHIMERA.54
Cocrystal structure with compound 1 was previously published.13
Figure 5. Stereogram of the compound 4 binding site. Two alternative binding poses of 4 (PDB code 4C27) are depicted in yellow and blue,
emphasizing flipping of the indole moiety in the vicinity of the heme macrocycle. The top face of the 4-trifluoromethyl substituted terminal unit
facing the viewer is solvent-exposed. Amino acid side chains (cyan) are shown within 5 Å. Heme is in gray spheres.
Figure 6. Buried binding mode. (A) van der Waals interactions
between the terminal N-phenyl rings of 1, 2, and 10 (yellow spheres)
and amino acid side chains (blue sticks). PDB codes of the
corresponding structures are shown in parentheses. (B) The fragment
of the 2fo − fc electron density map (blue mesh) contoured at 1σ
demonstrates unambiguous orientation of the terminal ring placing the
5-chloro substituent at van der Waals distances of V77, M358, M360,
I379, and A381. Heteroatoms are colored by types: oxygen in red,
nitrogen in blue, fluorine in cyan, chlorine in green. Heme is shown in
gray sticks. Distances in red are in angstroms. (C) Collective
substitution pattern of the terminal N-phenyl ring deduced from the
X-ray structure analysis and SAR. Superscript “a” indicates that
cocrystal structures with compounds 1 and 2 were previously
published.13
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typical for the P450 protein family; particularly affected are the
A′-helix in the β-domain and the F- and G-helices and the
spanning loop accommodating the short F′- and F″-helices in
the α-domain (Figure 7). The F″-helix experienced ∼35°
rotation angle difference between the buried and surface-
exposed terminal N-phenyl ring binding modes, resulting in
restructuring of the FG-loop and ∼10 Å repositioning of the
P216-R228 fragment.
Furthermore, conformational changes triggered by binding of
the terminal ring in the buried site affected the binding mode of
the invariant N-indolyloxopyridinyl-4-aminopropanyl portion
of the skeleton. Thus, in the 1, 2, and now 10 complexes, the
indole ring adopted a single well-defined conformation, tightly
enclosed by the electron-rich residues Y103, M106, F110, and
Y116.13 In the 3 and 4 complexes, binding ambiguity was
manifested in flipping of the indole ring (Figure 5).
Repositioning of the bulky aromatic side chains of Y103,
F110, and Y116, in response to the long substituent binding,
enlarged the size of the chamber adjacent to heme, allowing the
indole ring to flip. The same phenomenon has been reported
previously for the sulfonamide analog.28
■ DISCUSSION
Development of the N-indolyloxopyridinyl-4-aminopropanyl-
based series of CYP51 inhibitors was previously reported,
emphasizing the medicinal chemistry, drug metabolism, PK,
and CYP-binding properties of these compounds.13,26−28
Rounds of molecular modeling and inhibitor synthesis to
improve stability, selectivity, and potency ultimately led to
enhanced binding to the T. cruzi CYP51 target, enabling high-
resolution crystal structures to be obtained for the drug−target
complexes. One of the three newly reported X-ray structures
pushed the resolution limit for this protein drug target beyond
2.0 Å. Collectively, the cocrystal structures determined for the
N-arylpiperazine SAR series revealed a correlation between the
modification pattern of the terminal N-phenyl ring, binding
mode, and anti-T. cruzi activity of the compounds. The
following discussion is informed by the drug−target inter-
actions observed in our studies and by others.
The major structural elements defining inhibitor interactions
with the CYP51 drug target include (i) coordination to the
heme iron by the aromatic nitrogen atom of ring 1, (ii) both
nonspecific (with respect to the heme macrocycle) and target-
specific interactions of ring 2, and (iii) target-specific contacts
mediated by a third substituent at the molecular branching
point, often a carbon chiral center or tertiary amine, as in
fenarimol analogs (Figure 1). Both five-membered and six-
membered heterocycles are employed in CYP51 inhibitors as
iron-coordinating units.12 They provide nonspecific drug−
metal interactions which are modulated by repulsive or
attractive forces contributed by second aromatic functionality,
ring 2, or its fused equivalent in NEE and VNF. The geometry
of ring 2 interactions with the heme macrocycle varies
significantly depending on the degree of freedom allowed by
the inhibitor structure which is roughly proportional to the
distance between the Fe-ligating aromatic nitrogen in ring 1
and ring 2 functionality, expressed as number of bonds (n)
separating them: the shorter is the distance, the more coplanar
is the interaction between ring 2 and the heme macrocycle.
Thus, an energetically unfavorable sandwich geometry between
two aromatic systems is observed in UDD (Figure 1E) and JKF
(Figure 1F), n = 4, while in VNI, ring 2, having one extra bond
separating two functionalities, tilts with respect to the heme
tending to adopt a more attractive edge-on geometry (Figure
1C). Disposition of ring 2 and the heme macrocycle is also
affected by the rigidity of the connector. Thus, in the more rigid
structures of NEE (Figure 1B) and VNF (Figure 1D) (n = 8
and n = 7, respectively), the ring 2 fused equivalent tends to
offset the heme macrocycle to establish energetically more
favorable contacts. Finally, WVN (Figure 1A), n = 8, has the
most favorable T-shape stacking configuration, which is
consistent with about 2 orders of magnitude gain in binding
affinity, achieved in the parental scaffold by replacing the ethyl
moiety with tryptophan at the early stage of scaffold
development.29,37
The N-indoyloxypyridinyl-4-aminopropanyl-based scaffold is
one of two classes of CYP51 inhibitors that utilize six-
membered heterocycles to coordinate to the heme iron, the
other being the fenarimol-based scaffold.14−16 These two
compound series have significant differences in heme binding,
which have been previously reviewed.12,13 The energetically
more favorable edge-to-face π−π stacking interaction between
the heme macrocycle and the indole ring of the N-
indolyloxopyridinyl-4-aminopropanyl-based inhibitors (Figure
1A) contrasts with the virtually coplanar aromatic systems in
fenarimol analogs (Figure 1E). These differences may explain,
at least in part, differences in selectivity profiles of these
inhibitor classes over a panel of human drug-metabolizing
CYPs. Strong but nonspecific, the drug−heme interactions may
contribute to the attenuated selectivity of the N-indoyloxypyr-
idinyl-4-aminopropanyl-based compounds over a panel of
human CYPs.13
In general, all three major aspects of drug−target interactions
in CYP51 inhibitors are subject to optimization. In this work,
we focused on the drug−target contacts mediated by a third
substituent at the molecular branching point of the N-
indoyloxypyridinyl-4-aminopropanyl-based scaffold while re-
taining favorable T-shape geometry of the indole moiety
contact with heme macrocycle. This third and longest
substituent at the chiral carbon center confers the majority of
target-specific interactions and significantly contributes to
binding affinity.13 To gain binding specificity, a series of new
analogs focusing on the substitution pattern of the terminal N-
phenyl ring was synthesized and tested. The terminal N-phenyl
Figure 7. Solvent-exposed binding mode. (A) Superimposition of the
buried (yellow) and solvent-exposed (blue) binding mode structures
highlights protein conformational changes induced by the compound
10, compared to the compound 4 binding. Protein is represented by
the ribbon. Heme is in gray spheres. Distance in red is in angstrom.
The angle between F″ helices in superimposed structures is in degrees.
An insert on the left zooms in on the superimposed ligands (stick
mode) emphasizing differences between buried and solvent-exposed
conformations of the terminal N-phenyl ring.
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ring was shown previously to bind distal to the heme buried
hydrophobic cavity, the least conserved portion of the substrate
binding site across the CYP51 family.13 Depending on the ring
substitution pattern, an alternative ring binding mode was
observed in these studies. In compounds 3 and 4, carrying a
large chloro- or trifluoromethyl substituent at C-4, respectively,
the terminal ring was expelled from a buried into a solvent-
exposed environment, while in the analogs 1, 2, and 10, with no
substituent or a small substituent at C-4, the ring was
accommodated in a buried site (Figure 4).
On the basis of the X-ray structure analysis and accumulated
SAR data, an assumption was made that compounds 9 and 11−
12 may also bind fully buried in the protein interior, which
would be consistent with their high potency both in cell-based
assay and in the animal model (Table 1). Two of the most
optimized compounds belonging to this group, 9 and 10,
suppressed ≥99.8% parasitemia when administered at 25 mg/
kg, b.i.d., orally for 4 consecutive days. The observed trend of
potency and selectivity expanding upon increasing the size of
substituents in certain ring positions now allows fine-tuning
drug−target interactions to maximize selectivity and potency of
this class of T. cruzi inhibitors (Figure 5). For instance, the
accumulated data did not resolve a potential ambiguity which
may be caused by the compound 11 terminal N-phenyl ring
flipping within the buried site, suggesting that further ring
chlorination may be beneficial for the drug−target fit and hence
potency and specificity of this compound series. The atomic
details of drug−target interactions attained in this work
demonstrate the utility of cocrystal structures of the multiple
closely related representatives of the SAR series for refining hit-
to-lead optimization strategy.
Finally, binding in the buried mode of the terminal N-phenyl
unit in compounds 1, 2, and 10 allosterically stabilized in a
single conformation the invariable portion of the inhibitor
skeleton, the indolyl moiety, bound in vicinity of the heme
macrocycle. In contrast, binding of the terminal N-phenyl ring
of compounds 3 and 4 in the solvent-exposed mode was
accompanied by concomitant flipping of the indolyl moiety,
creating ambiguity illustrated by two alternative conformations
of 4 in Figure 5. On the basis of these observations, we
speculate that the allosteric component may be a key to
induced fit mechanism characterizing binding of the most
potent CYP51 inhibitors. This represents an additional
challenge to CYP51-targeted drug design, as modification
introduced at one end of a molecule may modulate the binding
mode at the other end.
■ CONCLUSIONS
The N-indoyloxypyridinyl-4-aminopropanyl-based inhibitors
represent a promising anti T. cruzi lead series, where potency,
selectivity, and metabolic stability are accreted through
medicinal chemistry efforts guided by the cocrystal structures
of the drug−target complexes. The SAR studies reported here
focused on the terminal N-phenyl ring of the N-arylpiperazine
series. A key role for the C-4 ring position in switching between
two alternative ring binding modes, buried and solvent-
exposed, has been recognized. Buried binding mode is
characterized by the terminal N-phenyl ring buried in the
protein interior. Binding of the terminal unit in the buried
mode induces concomitant stabilization of the binding of the
inhibitor indolyl moiety in the heme pocket. Inhibitors with the
bulky 5-chloro substituent bound in the buried mode were
more potent in the T. cruzi cell-based assay, exhibited higher
metabolic stability, and had better selectivity over human CYPs.
Particularly notable was the decline in inhibition of the most
persistent human isoform, CYP2C9, achieved by compound 9.
Compounds 9 and 10 also had excellent oral bioavailability and
exposure and higher efficacy in the animal model compared to
the previously reported closely related analogs 1 and 2. Further,
an attractive feature of the buried binding mode is its reduced
propensity for drug resistance, as the inhibitor binds within a
portion of the substrate envelope that is less prone to
mutagenesis as a result of prolonged drug exposure. The
knowledge gained in these studies opens the door to SAR fine-
tuning and rigorous assessment of compounds of the N-
indoyloxypyridinyl-4-aminopropanyl-based scaffold for para-
sitological cure in long-term animal models harboring more
virulent T. cruzi strains.
■ EXPERIMENTAL PROCEDURES
Chemistry. General Procedure for the Synthesis of
Inhibitors 1−13. To a solution of the appropriate benzoic acid
(∼1.2 equiv), PyBOP (∼1.4 equiv), and HOBt (∼10 mol %) in dry
CH2Cl2 (5 mL) was slowly added triethylamine (∼4 equiv) at ambient
temperature. The reaction mixture was stirred for 15 min until it
became homogeneous. D-Tryptophan derivative 26 was added, and the
reaction mixture was stirred at room temperature for 1 h. After
confirmation that the reaction was complete by using TLC analysis,
the solvent was removed under reduced pressure. Ethyl acetate (10
mL) was added to the crude product mixture, and this solution was
then washed with saturated aqueous NaHCO3 (2 mL × 2) and brine
(2 mL × 2). The organic layer was concentrated in vacuo, and the
crude product was directly subjected to flash chromatographic
purification to provide the title products.
(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-
yl)-4-(4-(3,5-dichlorophenyl)piperazin-1-yl)-2-fluorobenzamide TFA
(9). The general procedure was followed using carboxylic acid 21b as
the acylating agent. The crude product was further purified by HPLC
to afford 9 as a white solid (54%): 1H NMR (400 MHz, DMSO-d6) δ
11.47 (s, 1H), 10.93 (d, J = 2.5 Hz, 1H), 8.75−8.62 (m, 2H), 8.10−
7.90 (m, 3H), 7.60 (dd, J = 8.5, 6.7 Hz, 2H), 7.33 (d, J = 8.1 Hz, 1H),
7.26 (d, J = 2.4 Hz, 1H), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.00 (d, J
= 1.8 Hz, 2H), 6.94 (ddd, J = 8.0, 6.9, 1.0 Hz, 1H), 6.89 (t, J = 1.7 Hz,
1H), 6.87−6.76 (m, 2H), 4.86 (q, J = 6.7 Hz, 1H), 3.57−3.18 (m,
10H); 13C NMR (176 MHz, DMSO-d6) δ 172.98, 163.26, 162.19,
160.79, 158.06, 157.88, 154.06, 153.99, 152.28, 151.53, 143.88, 136.11,
134.67, 131.67, 131.65, 127.06, 124.10, 121.06, 118.33, 117.79, 117.21,
116.09, 114.36, 113.09, 111.42, 109.97, 109.90, 109.74, 108.89, 100.74,
100.58, 79.16, 78.97, 78.78, 55.47, 46.60, 46.18, 27.06; MS (ESI) m/z
631.2 [M + H]+; HRMS (ESI) m/z for C33H31N6O2FCl2 [M + H]
+
calcd 631.1791, found 631.1782.
(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-
yl)-4-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)-2-fluorobenza-
mide TFA (10). The general procedure was followed using carboxylic
acid 22b as the acylating agent. The crude product was further purified
by HPLC to afford 10 as a white solid (60%): 1H NMR (400 MHz,
DMSO-d6) δ 11.55 (s, 1H), 10.94 (d, J = 2.5 Hz, 1H), 8.77−8.59 (m,
2H), 8.06−8.02 (m, 2H), 7.99 (t, J = 6.8 Hz, 1H), 7.61 (dt, J = 9.1, 5.1
Hz, 2H), 7.33 (d, J = 8.1 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 7.25−7.17
(m, 1H), 7.09−7.01 (m, 3H), 6.98−6.90 (m, 1H), 6.90−6.78 (m, 2H),
4.87 (q, J = 6.7 Hz, 1H), 3.43 (dd, J = 6.5, 3.5 Hz, 4H), 3.39−3.18 (m,
2H), 2.97 (t, J = 4.9 Hz, 4H), 2.26 (s, 3H); 13C NMR (176 MHz,
DMSO-d6) δ 173.04, 163.30, 162.17, 160.76, 158.09, 157.90, 154.47,
154.40, 152.26, 151.80, 143.61, 136.11, 132.29, 131.64, 131.61, 130.76,
130.66, 127.06, 124.12, 122.77, 121.07, 119.07, 118.33, 114.41, 111.43,
110.07, 109.99, 109.85, 108.89, 100.86, 100.70, 55.50, 50.68, 47.17,
27.03, 17.20; MS (ESI) m/z 611.2 [M + H]+; HRMS (ESI) m/z for
C34H34N6O2FCl [M + H]
+ calcd 611.2338, found 611.2336.
Hepatic Microsomal Stability. Hepatic microsomal stability was
addressed as previously described.26
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CYP Inhibition. Cytochrome P450 inhibition was evaluated in
human liver microsomes using four selective marker substrates for
CYP1A2, CYP2C9, CYP2D6, and CYP3A4, as previously described.26
Compounds were tested at 1 μM.
Binding Affinity by UV−Visible Spectroscopy. Binding affinity
of compounds to CYP51 was approximated from the spectropho-
tometry titration curves as previously described.28,31 Spectra were
recorded using a Cary scanning spectrophotometer (Varian) in a 1 cm
path length quartz cuvette at 23 °C. Protein at 1 μM concentration in
1 mL of 100 mM potassium phosphate buffer (pH 7.5) containing
10% glycerol was titrated with 1 μL aliquots of test compound (100
μM in DMSO) ranging from 0.1 to 4 μM. The organic solvent effect
was compensated by adding the same volume of DMSO in the
reference cuvette containing protein.
Anti T. cruzi Activity in Cell-Based Assay. EC50 values of
compounds were determined in a cell-based assay performed in
triplicate as described elsewhere.31 Briefly, mouse C2C12 myoblasts
(ATCC no. CRL-1772) used to harbor parasites were cultivated in
Dulbecco’s modified Eagle medium H-21 containing 4.5 g/L glucose
(DMEM H-21), supplemented with 5% fetal bovine serum (FBS), 25
mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin. T. cruzi CA-I/72 trypomastigotes were obtained from
infected-culture supernatants after 4−7 days of infection. Cultures
were maintained at 37 °C with 5% CO2. The concentrations of
trypomastigotes and C2C12 cells were determined using a Neubauer
hemocytometer. Sterile, black 384-well plates with clear-bottom wells
(Greiner Bio-One) were seeded with 500 cells/well and then were
infected with 2500 parasites/well in a final volume of 50 μL/well.
Culture plates were incubated at 37 °C with 5% CO2 for 24 h. After
that, culture medium was removed and test compounds were added in
fresh medium. For this, an intermediate plate (384-well plate) was
prepared by serial dilution (10 mM, 2 mM, 400 μM, 80 μM, 16 μM, 3
μM, 128 nM, 25.6 nM, 5.1 nM) for all the compounds in 100%
DMSO. Then an amount of 50 nL of each sample was diluted in 50 μL
of medium (DMEM H-21) and added to the experimental plate
followed by incubation at 37 °C with 5% CO2 for 72 h. Wells
containing noninfected cells were used as a positive control (100% cell
survival), while T. cruzi infected but untreated cells (0% cell survival)
were used as a negative control. Cells were then fixed for 2 h with 4%
paraformaldehyde and rinsed with a solution of 150 mM NaCl, 100
mM NH4Cl, 0.1% Triton X-100, and 0.1% NaN3. After that, they were
treated for 4 h with 0.2 μg/mL the DNA fluorescent dye, DAPI (4,6-
diamidino-2-phenylindole), diluted in the same solution. Plates were
kept at ambient temperature until image acquisition was performed.
Images were acquired by an IN Cell Analyzer 2000 (GE Healthcare),
and the procedure and analyses were performed according to
previously described.31
Inhibition of Sterol Biosynthesis in Amastigotes. Sterol
profiling was performed on T. cruzi whole-cell lipid extracts, prepared
as described previously.51 Posaconazole (100 nM) was used as a
positive control, while benznidazole (5 μM) and K777 (1.6 μM)
served as negative controls. Compounds 9 and 10 were tested at 100
nM. Briefly, C2C12 mouse myoblasts were infected with T. cruzi
(CAI/72 strain) and treated with compounds after 72 h of infection.
After 24 h of treatment, the myoblast cells were detached, and the
lipids from cell pellet were extracted with chloroform/methanol,
chloroform, and acetonitrile, each step followed by several rounds of
washes with water to extract polar molecules. The organic layer was
then dried under nitrogen gas and subsequently treated with 75 μL of
N,N-bis(trimethylsilyl)-2,2,2-trifluoroacetamide (BSTFA) for 2 h at 37
°C to facilitate chemical derivatization with trimethylsilyl (TMS)
groups (BSTFA, Sigma-Aldrich). The TMS-derivatized lipid mixture
was analyzed by injecting 3 μL directly into an Agilent HP5790 gas
chromatography system outfitted with a DB5-MS analytical column
(30 m, 0.25 mm i.d., 0.33 μm film thickness, Agilent) coupled to a
mass selective detector. The lipids were separated on the analytical
column using a temperature profile that begins at 200 °C for 1 min,
increases by 15 °C/min to 300 °C, and then holds at 300 °C for 20
min. The inlet temperatures of the GC instrument and the MSD were
held at 250 and 300 °C, respectively. The mass spectrometer scanned
from m/z 50−750 during the course of analysis.
Animal Model. To assess in vivo efficacy of test compounds, a 4-
day mouse model of infection by transgenic T.cruzi Brazil luc strain,
former T. cruzi Y luc,34,35 expressing firefly luciferase was used as
previously described.13 Eight-week-old female Swiss Webster albino
mice (average weight 20 g) were obtained from Simonsen Labs
(Gilroy, CA). All animal protocols were approved and carried out in
accordance with the guidelines established by the Institutional Animal
Care and Use Committee from UCSF (approval no. AN087605-01).
Mice were housed at a maximum of 5 per cage and kept in a specific-
pathogen free (SPF) room at 20−24 °C under a 12 h light/12 h dark
cycle and provided with sterilized water and chow ad libitum. To infect
the mice, trypomastigote strains were harvested from culture
supernatant and injected intraperitonealy, 105 trypomastigotes per
mouse. Three control groups included untreated mice, which received
a vehicle, 20% Kolliphor HS 15 (also known as Solutol), and the
positive control groups, which received 25 or 50 mg/kg benznidazole,
all via oral gavage (po), twice a day (b.i.d). Starting on day 4 the
infected mice were treated with test compounds at 25 mg/kg
administered in 20% Kolliphor, po, b.i.d., for 4 consecutive days. On
day 7 postinfection, the luminescent signal in the mice was read upon
injection of D-luciferin. The absolute numbers of (measured photons/
s)/cm2 were averaged between all five mice in each group and
compared directly between compound-treated mice and the control
groups. Two-tailed paired Student t test was used to assess statistical
significance between luminescence values from vehicle-treated and
compound-treated groups on day 7 postinfection; values are
statistically significant when p ≤ 0.05.
Single Dose PK. Compounds were dose at 25 mg/kg in 8-week-
old female Swiss Webster albino mice over oral gavage. All compounds
were formulated to a concentration of 5 mg/mL in 20% Kolliphor/
80% water. Three mice were dosed with each compound, and n = 3
plasma samples were collected at approximately 0.25, 0.5, 1, 2, 4, 6, 8,
12, and 24 h after exposure. Plasma samples were treated with 5× v/v
acetonitrile to precipitate protein and filtered through a 0.2 μm filter
prior to analysis by LC−MS/MS using ABSciex 5500.
CYP51 Expression and Purification. Heterologous expression
and purification of recombinant T. cruzi CYP51 modified by replacing
the first 31 residues upstream of Pro32 with the fragment
MAKKTSSKGKL43 and by inserting a His6-tag at the C-terminus
were carried out according to the protocol described elsewhere.31,40
Briefly, 6 L of Terrific Broth medium supplemented with 100 μg/mL
ampicillin, 1 mM thiamine, and trace elements was inoculated with 60
mL of the overnight culture and was incubated at 28 °C, 230 rpm until
OD600nm reached 1.0. CYP51 expression was induced by adding 0.25
mM isopropyl-β-thiogalactopyranoside (IPTG), and 1 mM δ-amino-
levulinic acid, a precursor in heme biosynthesis, was added at that time.
After induction, the growth was continued at 18 °C at 180 rpm for 48
h. Cells were harvested, resuspended in 50 mM Tris, pH 8.5, 1 mM
EDTA, 100 mM NaCl, 0.5 mM PMSF, 1 mM DTT and lysed using a
microfluidizer. After centrifugation, the soluble fraction was purified by
conventional Ni-NTA agarose chromatography using a linear gradient
of imidazole (0−0.5 M) in 50 mM potassium phosphate, pH 8.0, 10%
glycerol, 1 mM DTT, 0.5 mM EDTA, 500 mM NaCl. After dialysis
overnight against 20 mM potassium phosphate, pH 7.5, 10% glycerol,
1 mM DTT, 0.5 mM EDTA, the sample was applied on MonoQ
column. The flow-through fractions were applied on Mono S column,
and the protein was eluted in the same buffer using linear NaCl
gradient (0−0.5 M). Fractions containing CYP51 were combined and
concentrated using Centriprep-50K concentrating device (Millipore).
These samples were stored at −80 °C and used as needed for
cocrystallization and binding assays.
X-ray Crystallography. To analyze the inhibitor binding mode,
recombinant T. cruzi CYP51 was used to obtain the cocrystal
structures with inhibitors. Concentrated purified protein samples were
diluted prior to crystallization to 0.1 mM by mixing with 20 mM
potassium phosphate, pH 7.5, 10% glycerol, 1 mM DTT, 0.5 mM
EDTA, 300 mM NaCl supplemented with equimolar inhibitor.
Crystallization conditions were determined using commercial high-
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throughput screening kits available in deep-well format (Hampton
Research), a nanoliter drop-setting Mosquito robot (TTP LabTech)
operating with 96-well plates, and a hanging drop crystallization
protocol. Crystals were further optimized in 96-well plates for
diffraction data collection and harvested directly from the 200 nL
drops. Prior to data collection, crystals were cryoprotected by plunging
them into a drop of reservoir solution supplemented with 20%
ethylene glycol, then flash-frozen in liquid nitrogen.
Diffraction data were collected at 100−110 K at beamline 8.3.1,
Advanced Light Source, Lawrence Berkeley National Laboratory, USA.
Data indexing, integration, and scaling were conducted using
MOSFLM44 and the programs implemented in the ELVES software
suite.45 The crystal structures were determined by molecular
replacement using diffraction data processed in the corresponding
space groups and atomic coordinates of T. cruzi CYP51 (PDB code
4C0C) as a search model. The final model was built using COOT,46
and refinement was performed by using REFMAC5 software.47,48 Data
collection and refinement statistics are shown in Table 3.
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